[PPT] - Neovasc Inc. TSXV: NVC Alexei Marko, CEO Chris Clark, CFO April PowerPoint Presentation

SLIDE 1

Neovasc Inc.

TSXV: NVC Alexei Marko, CEO Chris Clark, CFO April 2013

SLIDE 2

Forward-Looking Statements

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements. 2

SLIDE 3

Neovasc in Summary

A Canadian small cap medical device company with existing revenues & two development products:

3 Stage Product Growing Revenues Implantable biological tissue & services for transcatheter heart valves & other applications Late Stage Neovasc Reducer™ for treatment of refractory angina (CE marked) Early Stage Neovasc Tiara™ in preclinical development for treatment of mitral valve disease

SLIDE 4

Reducer Product

Treats Refractory Angina

Angina – Constant and severs heart pain caused by inadequate blood flow to

heart muscle

Refractory – Angina that cannot be managed through conventional drug,

catheter or surgical therapy

Large & growing population of untreatable patients

– Improved cardiac care leads to less mortality & more patients with advanced/end-stage disease

4

SLIDE 5

Reducer Method of Action

Venous back pressure causes more uniform distribution of blood flow through heart muscle

Forces more blood

into ischemic areas

Relieves angina

Reducer modulates outflow of blood from coronary veins, increasing blood flow to ischemic areas Reducer implanted in coronary sinus vein

Blood flow takes path of least resistance

Majority of blood flows

around ischemic areas

5

SLIDE 6

Reducer Procedure

Based on 1950’s surgical Beck Procedure
Reported excellent results but is no longer performed due to invasiveness
Reducer achieves same narrowing using modern non-surgical catheter-

based techniques

Reducer procedure takes 20 minutes; patient discharged within 24 hours
Safely provides treatment for an otherwise untreatable patient

CORONARY SINUS

6

SLIDE 7

Reducer Clinical Results

Compelling clinical data from 1st human trial (15 patients, 3 centers)

6-month data published in May 2007 JACC demonstrated safety & significant

improvement of angina symptoms

3-year follow-up data confirms excellent long-term safety & treatment

durability (presented at ACC, March 2010)

Average CCS Class Average Echo-Dobutamine Results Average Thalium SPECT Severity

Baseline 6-mos 3-yrs Baseline 6-mos 3-yrs Baseline 6-mos 3-yrs

7

SLIDE 8

Reducer COSIRA Trial

COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial

110-124 patients
Randomized 1:1 to blinded treatment & sham control arms
Primary endpoint: Efficacy @ 6-months
Sites in Belgium, Canada, UK, Denmark, Sweden & Netherlands
Complete enrollment in Q1 2013

Data will support European market launch & provide pilot data for US FDA trial

8

SLIDE 9

Reducer Timeline & Market Opportunity

Europe

CE mark received November 2011
Complete COSIRA enrollment in Apr/May 2013
Collect additional clinical data through registries initiated in Europe & Israel
Launch with distribution partner(s) following completion of COSIRA

United States

FDA IDE trial to be initiated following completion of COSIRA study

Market size

~2,000,000 existing “no option” refractory angina patients in US & Europe
~400,000 new “no option” patients diagnosed annually
~1,000,000 patients/year treated for “recurrent” angina

9

SLIDE 10

Biological Tissue and Services

Neovasc is a turnkey solution for industry partners developing medical devices that incorporate pericardial tissue Tissue

Proprietary process creates implantable, biocompatible tissue from animal

pericardium that retains strength & physical characteristics of natural tissue

Developed specifically for fabricating surgical heart valves
20+ year implant history, FDA-cleared, CE-marked, EDQM-certified
State-of-the-art laboratories & manufacturing facilities

Services

Tissue supply
Development & prototyping services
Pilot & commercial manufacturing

10

SLIDE 11

Transcatheter Heart Valve Applications

Neovasc is the leading independent supplier of biological leaflet material & related services to companies developing transcatheter heart valves

2011 sales of 1st generation transcatheter aortic valves $600M
2012 sales estimated $900M
Next generation devices reach commercialization in 2013/14
Wider use expected as valves improve
Currently supplying multiple programs
Broad services from simple tissue supply to full OEM valve manufacturing

11

SLIDE 12

Tiara Mitral Valve Replacement

Neovasc is developing Tiara, a novel transcatheter device for the treatment
f mitral regurgitation (MR)
MR is serious & widespread condition that can cause significant disability or

death

Significant portion of those with MR are non-surgical candidates
Tiara is a minimally-invasive device - delivered using a catheter inserted

through apex of heart to replace the diseased mitral valve

12

SLIDE 13

Tiara Key Features

Design is specific to mitral anatomy & matches natural shape of mitral

annulus

Resists high dislodgment forces during systole
Exerts minimal radial force on mitral annulus
Does not inhibit LV function or obstruct LVOT
Preserves native structures in LV (chordae, papillary muscles)
Implantation does not require rapid pacing & can be completed in less than 5

minutes after obtaining apical access

13

SLIDE 14

Tiara Development Timeline

Multiple patent applications filed
Refined valves & transapical delivery systems developed
Preclinical testing underway (bench, acute / chronic animal)
Durability (accelerated wear) testing underway
Clinical technique developed & refined through multiple animal implants
Expert medical advisory team assembled & active
Target first human implantation in 2013

14

SLIDE 15

15

Tiara Market Opportunity

Success of transcatheter aortic valves has positioned transcatheter mitral

valve replacement as major area of industry/clinical interest

600,000 new patients per year with MR in US & EU
Only 20% of diagnosed patients currently undergo surgery
Minimally invasive mitral valve replacement market potential estimated

at >$1B

SLIDE 16

Clinical Opinion Leaders

Leaders in interventional cardiology are assisting Neovasc programs

Dr. Shmuel Banai (Tel Aviv Medical Center)
Dr. Elazer Edelman (Harvard – MIT, Cambridge)
Dr. Tim Henry (Minneapolis Heart Institute)
Dr. Marc Jolicoeur (Montreal Heart Institute)
Dr. Martin Leon (Columbia University Medical Center, NYC)
Dr. William O’Neill (Miller School of Medicine, University of Miami)
Dr. Jean-Francois Tanguay (Montreal Heart Institute)
Dr. Stefan Verheye (Antwerp Cardiovascular Institute)
Dr. Chris White (Ochsner Medical Center, New Orleans)

16

SLIDE 17

Neovasc Looking Forward

Continued growth of tissue business

Steady growth in 2013
Upside potential as customers’ products commercialize in 2014 forward

Complete COSIRA trial for Reducer & pilot launch in Europe

Complete COSIRA enrollment in Apr/May 2013
Release full efficacy data after 6-month follow up in Q4 2013
Continue controlled EU release through REDUCE registries
Strategic partnership for wider EU launch in 2014
Develop plan for FDA approval and US market entry with Partner

Continued development of Tiara

Target first human study of Tiara in Q4 2013

17

SLIDE 18

Neovasc Recap

18 Product leader in 3 separate fields

Neovasc Tissue – Growing revenues & significant strategic value
Neovasc Reducer – CE marked & efficacy data in 2013
Neovasc Tiara – Successful acute animal studies & rapid advance to clinical

stage in 2013 Corporate Summary

Clean corporate structure 45.9m share issued, 55.8m fully diluted
Revenue growth of 50% over the last 4 years
$5.8m cash on hand at December 2012
Additional $4.2m from maturing in-the-money warrants and options in 2013
Key investors including Frost Group, Gagnon Securities and Peregrine

Ventures Public small cap opportunity in rapidly growing transcatheter valve space

SLIDE 19